A Phase 3 interventional study of Non-invasive Ventilation (NIV) and Continous Positive Airway Pressure (CPAP) in Chronic Obstructive Pulmonary Disease Exacerbation and Obstructive Sleep Apnea Exacerbation, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 8 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Assistance Publique - Hôpitaux de Paris.
Among the 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 19th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →7 of the 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 35+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 84 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 386 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 17 interventional studies, 102 across the 4 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05844462Phase 3Assistance Publique - Hôpitaux de ParisTadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease | 2027-10 |
| NCT07445750Assistance Publique - Hôpitaux de ParisSports Shoes and the Six-Minute Walk Test in COPD | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Chronic obstructive pulmonary disease (COPD) is a major public health problem with 212.3 million prevalent cases of COPD worldwide and 3.3 million deaths related to COPD in 2019. Obstructive sleep apnoea (OSA) is the most common sleep disordered breathing. It is estimated that almost 1 billion adults have OSA worldwide.
Given the increasing prevalence of obesity, co-morbid OSA is frequently seen in patients with COPD. Co-morbid OSA has been shown to increase mortality, to reduce quality of life and to favour acute exacerbation of COPD. For those admitted for a life-threatening exacerbation of COPD requiring an intensive care admission for acute hypercapnic failure, they are more likely to get readmitted. For those admitted for an acute exacerbation in any ward, they are more likely to be re-admitted for another exacerbation within 180-days if their OSA is not treated.
Unfortunately, data regarding the best management of OSA in patients with co-morbid COPD are lacking as they were often excluded from clinical trials involving patients with COPD. Therefore, CPAP or NIV are administered without scientific evidence establishing which treatment is the most appropriate.
Patients admitted for a severe exacerbation of COPD that required NIV or invasive ventilation or high flow therapy will be screened for the trial once they reach clinical stability that allow weaning of NIV, invasive ventilation, or high flow therapy.
The screening visit will take place during a standard consultation between 2 days following admission for acute hypercapnic respiratory failure and no later than 30 days following the discharge from the acute ward.
The inclusion visit will be performed no later than 30-days following discharge from the acute ward.
Follow-up visits will be performed at 3, 6 months after inclusion with a +/-14 days window.
Visits will be conducted in the hospital unless patient is unable to attend due to medical condition or healthcare crisis (infectious pandemic for example). In that case, a remote consultation will be performed to retrieve data available without physical attendance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomised to the intervention arm will be established on NIV before discharge to home.
Device: Non-invasive Ventilation (NIV)
Patients randomised to the control arm will be established on CPAP before discharge to home.
Device: Continous Positive Airway Pressure (CPAP)
Patients will receive a dedicated training for the use of their NIV in the home setting. The training is the same provided in the usual care of patients established on NIV. They will choose a home care provider for the delivery of NIV as per standard care in France. A telemonitoring of adherence to NIV will be performed.
Patients will receive a dedicated training the use of their CPAP in the home setting. The training is the same provided in the usual care of patients established on CPAP. They will choose a home care provider for the delivery of CPAP as per standard care in France. Follow-up of CPAP will be performed according to standard care in France and will therefore include a telemonitoring of adherence to CPAP.
Demonstrate the superiority of home NIV versus home CPAP for the reduction of severe exacerbation of COPD or death.
Reduction of severe exacerbation of COPD or death, defined by the time to occurrence of (i) death from any cause or (ii) hospitalization in relation to severe exacerbation of COPD during a follow up of 12 months after randomization.
Time frame: 0-12 months from inclusion
Evaluate the benefit of NIV over CPAP regarding control of sleep disordered breathing
Control of sleep disordered breathing, defined as evolution between baseline and 1 year follow-up of the following combined criteria : * Apnea-hypopnea index (whilst unsupported breathing at baseline and when using the treatment overnight) * 3% Oxygen desaturation index (whilst unsupported breathing at baseline and when using the treatment overnight) * Proportion of time spent with SpO2 \<90% (whilst unsupported breathing at baseline and when using the treatment overnight) * Change in 3% Oxygen desaturation index between baseline at 3- and 6-months follow-up when using the treatment overnight * Proportion of time spent with SpO2 \<90% at 3 months and 6 months when using the treatment overnight.
Time frame: 0-12 months from inclusion
Quality of life of NIV over CPAP
HRQOL compared at 3 months follow-up using HRQOL questionnaires.
Time frame: At month 3
Quality of life of NIV over CPAP
HRQOL compared at 12 months follow-up using HRQOL questionnaires.
Time frame: At month 12
Quality of sleep of NIV over CPAP (Pittsburgh Sleep Quality Index).
Change in quality of sleep will be assessed using quality of sleep evaluation scales (Pittsburgh Sleep Quality Index).
Time frame: From Day 1 to Day 90
Quality of sleep of NIV over CPAP
Change in quality of sleep will be assessed using quality of sleep evaluation scales (Epworth Sleepiness Scale).
Time frame: From Day 1 to Day 90
Quality of sleep of NIV over CPAP (Insomnia Severity Index).
Change in quality of sleep will be assessed using quality of sleep evaluation scales (Insomnia Severity Index).
Time frame: From Day 1 to Day 90
Quality of sleep of NIV over CPAP
Change in quality of sleep will be assessed using the difference from baseline and one-year follow-up using quality of sleep evaluation scales (Pittsburgh Sleep Quality Index).
Time frame: From Day 1 to Day 365
Quality of sleep of NIV over CPAP
Change in quality of sleep will be assessed using the difference from baseline and one-year follow-up using quality of sleep evaluation scales (Epworth Sleepiness Scale).
Time frame: From Day 1 to Day 365
Quality of sleep of NIV over CPAP (Insomnia Severity Index).
Change in quality of sleep will be assessed using the difference from baseline and one-year follow-up using quality of sleep evaluation scales (Insomnia Severity Index).
Time frame: From Day 1 to Day 365
Quality of sleep of NIV over CPAP in centres that will perform overnight polysomnography
Quality of sleep,defined by variations between day 1 and 1 year in objective measures of sleep quality in centres that will perform overnight polysomnography : proportions of light, deep and REM sleep, wake since sleep onset, awakenings, arousals, sleep efficacy, sleep efficiency.
Time frame: From Day 1 to Day 365
Respiratory function benefit of NIV over CPAP
Respiratory function defined as change in gas exchange from baseline (Pa02, PaCO2) and 1 year: Arterial blood gas (ABG) will be measured during daytime and will be performed after 30 min on room air).
Time frame: From Day 1 to Day 365
Respiratory function benefit of NIV over CPAP
Respiratory function defined as change in Forced Expiratory Volume 1, at 1 year.
Time frame: At month 12
Exercise capacity benefit of NIV over CPAP
Exercise capacity defined as change in distance walked during a 6MWT. 6MWT will be performed at discharge and at each follow-up visit. 6MWT will be performed according to ERS guidelines.
Time frame: At month 3
Exercise capacity benefit of NIV over CPAP
Exercise capacity defined as change in distance walked during a 6MWT at 1 year. 6MWT will be performed at discharge and at each follow-up visit. 6MWT will be performed according to ERS guidelines.
Time frame: At month 12
Benefit of compliance and tolerance of NIV over CPAP
Compliance of the treatment, defined as Daily use / % of day used \>4hours / side effect questionnaire, assessed at each visit.
Time frame: From Day 1 to Day 90
Benefit of compliance and tolerance of NIV over CPAP
Compliance of the treatment, defined as Daily use / % of day used \>4hours / side effect questionnaire, assessed at each visit.
Time frame: From Day 1 to Day 180
Benefit of compliance and tolerance of NIV over CPAP
Compliance of the treatment, defined as Daily use / % of day used \>4hours / side effect questionnaire, assessed at each visit.
Time frame: From Day 1 to Day 365
Benefit of NIV over CPAP regarding usefulness of CPAP/NIV data to predict COPD severe acute exacerbation.
Change in breathing frequency or other extractable parameters that may predict the onset of a severe exacerbation.
Time frame: At month 12
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Oct 2029, 40 months after the start.
Of 33 non-industry phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's planned 40 months is close to that.
Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Assistance Publique - Hôpitaux de Paris →